NEW YORK (GenomeWeb News) – Newly formed Selah Genomics today announced that it has acquired EnGenCore for an undisclosed amount.
Selah CEO Michael Bolick said in a statement that the purchase of EnGenCore will lead to the development of "molecular and genomic technology at [the University of South Carolina] with an eye toward helping translate this impactful technology to the clinic." The firm's Clinical Genomics Center is located at the GHS Institute for Translational Oncology Research in close proximity to the USC medical school, he noted.
Last week, UK-based Lab 21 sold its laboratory assets in South Carolina to the newly formed Selah, and Bolick formerly served as president of the US subsidiary of Lab21.
EnGenCore was spun out of the University of South Carolina in 2008 and provides sequencing services. It uses the Roche 454 platform and its clients include Pfizer, Bristol-Myers Squibb, and the Howard Hughes Medical Institute, according to its website.
Bolick told GenomeWeb Daily News that Selah also has platforms from Illumina, Life Technologies, and Pacific Biosciences and noted that his firm will "offer a platform-agnostic service where we match the particular strengths of each platform to a customer's particular project."